CLC Number:
| [1] 徐德超,马熠熠,梅长林.托伐普坦治疗快速进展型常染色体显性多囊肾病的临床实践指南解读[J].中华肾脏病杂志,2019,35(5):387-392. XU Dechao, MA Yiyi, MEI Changlin. Interpretation of the clinical practice guideline for treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan[J]. Chinese Journal of Nephrology, 2019, 35(5):387-392. [2] Harris PC. 2008 Homer W. Smith Award:insights into the patho genesis of polycystic kidney disease from gene discovery [J]. J Am Soc Nephrol, 2009, 20(6):1188-1198. [3] Nash DA Jr. Hypertension in polycystic kidney disease without renal failure[J].Arch Intern Med,1977,137(11):1571-1575. [4] Chapman AB, Johnson A, Gabow PA, et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease[J]. N Engl J Med,1990,323(16):1091-1096. [5] Torres VE, Donovan KA, Scicli G, et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease[J]. Kidney Int,1992, 42(2):364-373. [6] Loghman-Adham M, Soto CE, Inagami T, et al. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease[J]. Am J Physiol Renal Physiol, 2004, 287(4):775-788. [7] Ramanathan G, Elumalai R, Periyasamy S, et al. Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease[J]. Iran J Kidney Dis, 2014, 8(4):265-277. [8] Hirai H, Kanno M, Watanabe T, et al. Kidney dysfunction following adrenalectomy in autosomal dominant polycystic kidney disease complicated with primary aldosteronism: A case report[J]. Exp Ther Med, 2017,14(2):1235-1240. [9] Conn JW,Louis LH. Primary aldosteronism,a new clinical entity [J]. Ann Intern Med,1956,44(1):1-15. [10] Funder JW, Carey RM, Mantero F, et al. the management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2016, 101(5):1889-1916. [11] Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens, 2013, 31(7):1465-1471. [12] 蒋怡然,王卫庆. 原发性醛固酮增多症在中国的诊治现状及研究进展[J]. 中华内分泌代谢杂志,2018,34(9):717-720. JIANG Yiran, WANG Weiqing. Diagnosis, treatment and progress of primary aldosteronism in China[J]. Chinese Journal of Endocrinology and Metabolism, 2018, 34(9):717-720. [13] 赖凤华,曹筱佩,林慧美,等.两种血浆肾素、醛固酮检测方法对原发性醛固酮增多症筛查效率的评价[J]. 中华高血压杂志,2015,23(2):150-153. LAI Fenghua, CAO Xiaopei, LIN Huimei, et al. Comparison of plasma renin and aldosterone measured by radioimmunoassay and chemiluminescence immunoassay in screening primary aldosteronism[J]. Chinese Journal of Hypertension, 2015, 23(2):150-153. [14] Saeki S, Ogihara T, Masugi F, et al. A case of primary aldosteronism with polycystic kidney disease[J]. Nihon Naika Gakkai Zasshi,1986,75(1):28-32. [15] Franchini M, Mannucci PM. The history of hemophilia[J]. Semin Thromb Hemost, 2014, 40(5):571-576. [16] 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 血友病诊断与治疗中国专家共识(2017年版)[J]. 中华血液学杂志, 2016, 37(5):364-370. Thrombosis and Hemostasis Group, Hematology Societ. Consensus of Chinese expert on the diagnosis and treatment of hemophilia(version 2017)[J]. Chinese Journal of Hematology, 2016, 37(5):364-370. |
| No related articles found! |
|
||
